Related Experiment Video
Updated: May 1, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal
Katharina Seystahl1, Michael Weller, Oliver Bozinov
1Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Background:
Antiangiogenic treatment has been explored in few patients with hemangioblastoma after failure of surgery and radiotherapy.
Case Report:
We present the first histopathological follow-up study of a bevacizumab-responsive hemangioblastoma that eventually progressed. For a period of 12 months, therapy with bevacizumab achieved a clinical response and radiological stabilization in a patient with progressive multifocal central nervous system (CNS) hemangioblastoma. Subsequently, selected tumor sites showed radiological progression, in particular, the formation of an intramedullary lesion of the initially predominantly leptomeningeal disease. Histology showed diffuse dural invasion by the hemangioblastoma accompanied with a relatively reduced cell density compared to the preserved vessel structures.
Conclusion:
The pattern of progression upon vascular endothelial growth factor (VEGF)-targeting antiangiogenic treatment in hemangioblastoma may involve increased tumor invasiveness.
